학술논문
Activities and concentration of alpha-1 antitrypsin and cystatin C in serum from patients with house dust mite asthma.
Document Type
Academic Journal
Author
Hidayati MD; Master's Program in Biomedical Sciences, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.; Iswanti FC; Master's Program in Biomedical Sciences, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.; Department of Biochemistry and Molecular Biology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.; Djauzi S; Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia.; Koesnoe S; Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia.; Sadikin M; Master's Program in Biomedical Sciences, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.; Department of Biochemistry and Molecular Biology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
Source
Publisher: Wolters Kluwer Country of Publication: Netherlands NLM ID: 101561954 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2233-8276 (Print) Linking ISSN: 22338276 NLM ISO Abbreviation: Asia Pac Allergy Subsets: PubMed not MEDLINE
Subject
Language
English
ISSN
2233-8276
Abstract
Background: The proteolytic activities of house dust mite (HDM) allergens are involved in the pathogenesis of asthma by cleaving T-junction protein complexes, increasing the permeability of airway epithelial cells, and enabling the allergens to reach the interstitial tissue. The human body contains natural protease inhibitors such as alpha-1 antitrypsin (AAT) with antiserine protease activity and cystatin C with anticysteine protease activity.
Objective: This study aimed to investigate the behavior of serum AAT and cystatin C levels in patients with HDM-allergic asthma.
Methods: Ten individuals with HDM-allergic asthma and 10 healthy volunteers participated in a cross-sectional study. The serum AAT and cystatin C inhibitory activities were measured using enzymatic assays. ELISA was used to determine the serum AAT and cystatin C concentrations.
Results: Serum AAT inhibitory activity ( P = 0.445; P > 0.05), AAT concentration ( P = 0.290; P > 0.05), and cystatin C concentration ( P = 0.419; P > 0.05) did not significantly differ between the patient and control groups. However, serum cystatin C inhibitory activity in the asthmatic patient group was significantly higher than in the healthy subjects ( P = 0.001; P < 0.05). There was no correlation between AAT inhibitory activity and AAT concentration or between cystatin C inhibitory activity and cystatin C concentration.
Conclusion: These findings suggest that serum cystatin C activity is involved in asthma pathogenesis. Additional research is required to address this issue.
Competing Interests: The authors have no financial conflicts of interest.
(Copyright © 2023. Asia Pacific Association of Allergy, Asthma and Clinical Immunology.)
Objective: This study aimed to investigate the behavior of serum AAT and cystatin C levels in patients with HDM-allergic asthma.
Methods: Ten individuals with HDM-allergic asthma and 10 healthy volunteers participated in a cross-sectional study. The serum AAT and cystatin C inhibitory activities were measured using enzymatic assays. ELISA was used to determine the serum AAT and cystatin C concentrations.
Results: Serum AAT inhibitory activity ( P = 0.445; P > 0.05), AAT concentration ( P = 0.290; P > 0.05), and cystatin C concentration ( P = 0.419; P > 0.05) did not significantly differ between the patient and control groups. However, serum cystatin C inhibitory activity in the asthmatic patient group was significantly higher than in the healthy subjects ( P = 0.001; P < 0.05). There was no correlation between AAT inhibitory activity and AAT concentration or between cystatin C inhibitory activity and cystatin C concentration.
Conclusion: These findings suggest that serum cystatin C activity is involved in asthma pathogenesis. Additional research is required to address this issue.
Competing Interests: The authors have no financial conflicts of interest.
(Copyright © 2023. Asia Pacific Association of Allergy, Asthma and Clinical Immunology.)